Induction of apoptosis and necrosis in lymphocytes by the cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 558, Issue 1-2, 2004, Pages 169-179

  Kosmider, Beata ^a   Osiecka, Regina ^a   Ciesielska, Ewa ^b   Szmigiero, Leszek ^b   Zyner, Elzbieta ^b   Ochocki, Justyn ^b  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; cis Diamminedichloroplatinum(II); cis bis(3 Aminoflavone)dichloroplatinum(II); Lymphocytes; Necrosis

Indexed keywords

BIS(3 AMINOFLAVONE)DICHLOROPLATINUM; CISPLATIN; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DEGRADATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; LYMPHOCYTOTOXICITY; NECROSIS; PRIORITY JOURNAL;

EID: 1242317081     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2003.12.004     Document Type: Article

References (39)

1. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99:1999;2467-2498.
2. B.I. Sikic, Antineoplastic agents, in: C.R. Craig, R.E. Stitzel (Eds.), Modern Pharmacology, Little, Brown and Company, Boston, 1982, p. 787.
3. Ferguson L.R., Pearson A.E. The clinical use of mutagenic anticancer drugs. Mutat. Res. 355:1996;1-12.
4. Sanderson B.J.S., Ferguson L.R., Denny W.A. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat. Res. 355:1996;59-70.
5. Waters M.D., Stack H.F., Jackson M.A. Genetic toxicology data in the evaluation of potential human environmental carcinogens. Mutat. Res. 437:1999;21-49.
6. Dauzonne D., Folléas B., Martinez L., Chabot G.G. Synthesis and in vitro cytotoxicity of a series of 3-aminoflavones. Eur. J. Med. Chem. 32:1997;71-82.
7. Kuntz S., Wenzel U., Daniel H. Comparative analysis of the effects of flavonoids on proliferation. Eur. J. Nutr. 38:1999;133-142.
8. Nijveldt R.J., Nood E., Hoorn D.E.C., Boelens P.G., Norren K., Leeuwen P.A.M. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74:2001;418-425.
9. Vermes I., Haanen C. Apoptosis and programmed cell death in health and disease. Adv. Clin. Chem. 31:1994;146-177.
10. Vermes I., Haanen C., Reutelingsperger C. Flow cytometry of apoptotic cell death. J. Immunol. Methods. 243:2000;167-190.
11. J. Ochocki, E. Zyner, 2003. Patent Nr. P.185585.
12. Lieberthal W., Triaca V., Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am. Physiol. Soc. 3:1996;F700-F708.
13. Leite M., Quinta-Costa M., Leite P.S., Guimarães J.E. Critical evaluation of techniques to detect and measure cell death - study in a model of UV radiation of the leukaemic cell line HL60. Anal. Cell. Pathol. 19:1999;139-151.
14. Elstein K.H., Zucker R.M. Comparison of cellular and nuclear flow cytometric techniques for discriminating apoptotic subpopulations. Exp. Cell Res. 211:1994;322-331.
15. Gasiorowski K., Brokos B., Kulma A., Ogorzalek A., Skorkowska K. A comparison of the methods applied to detect apoptosis in genotoxically-damaged lymphocytes cultured in the presence of four antimutagens. Cell. Mol. Biol. Lett. 6:2001;141-159.
16. Machoñ Z., Wieczorek Z., Zimecki M. Immunotropic activity of Vratizolin (ITCL, Dentovir). Pol. J. Pharmacol. 53:2001;377-383.
17. Carmichael J., DeGraff W., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:1987;936-942.
18. Borner M.M., Jonocourt F., Hotz M.A. Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells. Brit. J. Cancer. 76:1997;1448-1454.
19. Reedijk J. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem. Rev. 99:1999;2410-2499.
20. Gonzalez V.M., Fuertes M.A., Alonso C., Perez J.M. Is cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol. 59:2001;657-663.
21. Lee R.H., Song J.M., Park M.Y., Kang S.K., Kim Y.K., Jung J.S. Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem. Pharmacol. 62:2001;1013-1023.
22. Racz I., Tory K., Gallyas F., Berente Z., Osz E., Jaszlits L., Bernath S., Sumegi B., Rabloczky G., Literati-Nagy P. BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem. Pharmacol. 63:2002;1011-1099.
23. Sakagami H., Jiang Y., Kusama K., Atsumi T., Ueha T., Toguchi M., Iwakura I., Satoh K., Fukai T., Nomura T. Induction of apoptosis by flavones. Anticancer Res. 20:2000;271-278.
24. Robles S.J., Buehler P.W., Negrusz A., Adami G.R. Permanent cell cycle arrest in asynchronously proliferating normal human fibroblasts treated with doxorubicin or etoposide but not camptothecin. Biochem. Pharmacol. 58:1999;675-685.
25. Boos G., Stopper H. Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol. Lett. 116:2000;7-16.
26. Domínguez I., Pastor N., Mateos S., Cortés F. Testing the SCE mechanism with non-poisoning topoisomerase II inhibitors. Mutat. Res. 497:2001;71-79.
27. Boege F., Straub T., Kehr A., Boesenberg C., Christiansen K., Andersen A., Jakob F., Köhrle J. Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I. J. Biol. Chem. 271:1996;2262-2270.
28. Ormerod M.G., O'Neill C.F., Robertson D., Harrap K.R. Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp. Cell Res. 211:1994;231-237.
29. Schulze-Osthoff K., Walczak H., Dröge W., Krammer P.H. Cell nucleus and DNA fragmentation are not required for apoptosis. J. Cell Biol. 127:1994;15-20.
30. Bortner C.D., Cidlowski N.B.E., Oldenburg J.A. The role of DNA fragmentation in apoptosis. Trends Cell Biol. 5:1995;21-26.
31. Sakahira H., Enari M., Ohsawa Y., Uchiyama Y., Nagata S. Apoptotic nuclear morphological change without DNA fragmentation. Cur. Biol. 9:1999;543-546.
32. Cregan S.P., Smith B.P., Brown D.L., Mitchel R.E.J. Two pathways for the induction of apoptosis in human lymphocytes. Int. Radiat. Biol. 75:1999;1069-1086.
33. Eastman A. Activation of programmed cell death by anticancer agent: cisplatin as a model system. Cancer Cells. 2:1990;275-280.
34. A. Eastman, M.A. Barry, C. Demarcq, The involvement of the cell cycle in apoptosis, in: V.W. Hu (Ed.), The Cell Cycle: Regulators, Targets and Clinical Applications, Plenum Press, New York, 1994, pp. 369-378.
35. Ciesielska E., Studzian K., Zyner E., Ochocki J., Szmigiero L. DNA damage and apoptosis induction in L1210 cells by cis- diamminedichloroplatinum(II) and its new aminoflavone analogue. Cell Mol. Biol. Lett. 5:2000;441-450.
36. Jakupec M.A., Galanski M., Keppler B.K. Tumour-inhibiting platinum complexes-state of the art and future perspectives. Rev. Physiol. Biochem. Pharmacol. 146:2003;1-53.
37. B. Kosmider, K. Wyszynska, E. Janik-Spiechowicz, R. Osiecka, E. Zyner, J. Ochocki, E. Ciesielska, W. Wasowicz, Evaluation of the genotoxicity of cis-bis(3-aminoflavone)dichloroplatinum(II) in comparison with cis-DDP, Mutat. Res. (2004) in press.
38. Pietras T., Kakowski R., Zyner E., Stolarek R., Ochocki J., Musial A., Nowak D., Glinka R. Deoxyribose degradation by cis-platinum and its derivatives choline, hydroaspartate and aminoflavone. J. Cosmet. 4:1998;177-180.
39. Zyner E., Graczyk J., Ochocki J. Pt(II) and Pd(II) complexes of 3-aminoflavone: in vitro and in vivo evaluation. Pharmazie. 54:1999;945-946.